Novartis Pharma

Enanta, Novartis collaborate to advance Hep C inhibitor

Wednesday, February 22, 2012 01:53 PM

Enanta Pharmaceuticals, a developer of best-in-class small molecule drugs in the infectious disease field, has formed an exclusive collaboration and license agreement with Novartis for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, a hepatitis C virus inhibitor.

More... »


Unigene appoints Mayes and Pepper to biotechnologies SBU

Friday, February 10, 2012 11:48 AM

Unigene Laboratories announced the expansion of its biotechnologies strategic business unit (SBU) with the promotion of Gregory T. Mayes to chief business officer and appointment of Jane Pepper to senior director, business development.

More... »


Vanda begins trial for long-acting injectable to treat schizophrenia

Monday, April 11, 2011 12:52 PM

Vanda Pharmaceuticals and Novartis Pharmaceuticals, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable (or depot) formulation of Fanapt (iloperidone).  This is a phase I study that will evaluate the safety and pharmacokinetic profiles of two different long-acting formulations of Fanapt in patients with schizophrenia.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs